Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rituximab added to CODOX-M/IVAC is highly effective in HIV-negative and HIV-positive Burkitt lymphoma

Abramson JS, Barnes JA, Toomey CE, Jacobsen ED, Armand P, Takvorian T, Fisher DC, Reynolds H, Hochberg EP, LaCasce AS. Rituximab added to CODOX-M/IVAC is highly effective in HIV-negative and HIV-positive Burkitt lymphoma. Blood. 2008; 112:3595.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.